News

Antisoma has reported that the ATTRACT-1 phase III trial of ASA404 in non-small cell lung cancer (NSCLC) has reached its enrolment target of 1,200 patients. ASA404 is a

Integrated DNA Technologies (IDT) has been awarded $99,750 by the National Institutes of Health ARRA (American Recovery and Reinvestment Act) funding to continue work on its research project

Stemedica Cell Technologies (Stemedica) has been granted a license by the State of California’s Food & Drug Branch to manufacture stem cells for human clinical trials. The Drug

Gene Signal has reported the publication of interim results from a phase II study suggesting that the antisense oligonucleotide GS-101 is safe and effective at inhibiting and regressing

ACADIA has reported top-line results from the first pivotal phase III trial with pimavanserin in patients with Parkinson’s disease psychosis, or PDP. Reportedly, the study did not meet

Studies conducted by Kowa showed that the patients treated with Livavo (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C)

Tioga Pharmaceuticals (Tioga) and Ono Pharmaceutical (Ono) has entered into an exclusive license agreement under which Ono has licensed rights to develop and commercialise asimadoline in Japan, South

ResearchPoint has announced the formation of a new resource management organization. The affiliate organization, ResourcingPoint, has been spun-off to provide contract clinical research associates (CRAs) to meet Sponsors’

Shire has completed its submission of a New Drug Application (NDA) for velaglucerase alfa, its enzyme replacement therapy in development for the treatment of Type 1 Gaucher disease,